Novavax, Inc. (NASDAQ:NVAX) has analysts on the Bullish side this week.

Novavax, Inc. (NASDAQ:NVAX) Logo
Investors sentiment decreased to 0.93 in Q3 2018. Its down 1.18, from 2.11 in 2018Q2. It dropped, as 18 investors sold Novavax, Inc. shares while 37 reduced holdings. 23 funds opened positions while 28 raised stakes. 152.30 million shares or 5.09% less from 160.47 million shares in 2018Q2 were reported.
Quantitative Ltd Liability reported 50,800 shares. 12,000 are held by Barry Investment Advisors Ltd. Boothbay Fund Management Lc reported 20,541 shares. Da Davidson And has invested 0% in Novavax, Inc. (NASDAQ:NVAX). Duncker Streett & Communication has invested 0% in Novavax, Inc. (NASDAQ:NVAX). Voya Invest Mngmt Ltd Liability Corp stated it has 152,002 shares. Lpl has 0% invested in Novavax, Inc. (NASDAQ:NVAX). State Board Of Administration Of Florida Retirement Sys invested 0% of its portfolio in Novavax, Inc. (NASDAQ:NVAX). Deutsche Comml Bank Ag has 1.07M shares for 0% of their portfolio. Clear Harbor Asset Mngmt Limited Liability holds 0.01% or 19,500 shares in its portfolio. Rock Springs Mgmt L P owns 3.25M shares. Regentatlantic Ltd Liability accumulated 80,000 shares. Advisory Services Network Limited Liability owns 3,200 shares. Manufacturers Life Company The invested in 0% or 253,549 shares. Baker Bros Advsr L P holds 0.06% of its portfolio in Novavax, Inc. (NASDAQ:NVAX) for 4.72M shares.

Since July 31, 2018, it had 1 buy, and 0 insider sales for $11,446 activity.

Novavax, Inc. (NASDAQ:NVAX) Ratings Coverage

Among 3 analysts covering Novavax (NASDAQ:NVAX), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Novavax had 3 analyst reports since September 21, 2018 according to SRatingsIntel. JP Morgan upgraded the stock to “Overweight” rating in Friday, September 21 report. The firm has “Overweight” rating given on Monday, November 26 by PiperJaffray. Below is a list of Novavax, Inc. (NASDAQ:NVAX) latest ratings and price target changes.

11/12/2018 Broker: Oppenheimer Rating: Outperform New Target: $4 Initiates Coverage On
26/11/2018 Broker: PiperJaffray Old Rating: Neutral New Rating: Overweight Upgrade
21/09/2018 Broker: JP Morgan Old Rating: Underweight New Rating: Overweight Upgrade

The stock decreased 3.86% or $0.085 during the last trading session, reaching $2.115. About 5.06M shares traded. Novavax, Inc. (NASDAQ:NVAX) has risen 51.77% since January 14, 2018 and is uptrending. It has outperformed by 51.77% the S&P500.

Novavax, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. The company has market cap of $809.73 million. The firm develops respiratory syncytial virus fusion protein nanoparticle vaccine candidate for infants via maternal immunization in Phase III development stage; older adults in Phase II development stage; and children six months to five years of age in Phase I development stage. It currently has negative earnings. It also develops Ebola GP vaccine in Phase 1 clinical trial; preclinical programs for Zika virus; and seasonal influenza and a combination respiratory vaccine candidate, as well as other infectious disease vaccine candidates.

Novavax, Inc. (NASDAQ:NVAX) Institutional Positions Chart

(adsbygoogle = window.adsbygoogle || []).push({});

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.